»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024³â 1¾ï 1,452¸¸ ´Þ·¯¿¡¼ 2031³â±îÁö 1¾ï 8,930¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£(2025-2031³â)¿¡ CAGR 7.36%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.
ÇöÀç, Àΰ£¿ë ÇÕ¼º ÆéƼµå ¹é½ÅÀº ¸ðµÎ ¿¬±¸°³¹ß/½ÃÇè ´Ü°è¿¡ ÀÖÀ¸¸ç, Ãâ½ÃµÈ °ÍÀº ÁÖ·Î µÅÁö ±¸Á¦¿ª ¹é½Å µîÀÇ µ¿¹°¿ë ¹é½Å »ÓÀÔ´Ï´Ù.
Áß±¹ÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024³â 9,824¸¸ ´Þ·¯¿¡¼ 2031³â±îÁö 1¾ï 6,182¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2025-2031³â) CAGRÀº 7.29%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü´Â United Biomedical, CAHIC, Xinjiang Tecon, ISA Pharmaceuticals, Lytix Biopharma, Merck, OncoTherapy Science, Circio, Stemline Therapeutics, Treos Bio µîÀÔ´Ï´Ù.
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, °¢ Áö¿ª ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÁÖ¿ä ±â¾÷ ¼øÀ§, ½ÃÀå Á¡À¯À² µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹üÀ§
ÇÕ¼º ÆéƼµå ¹é½Å Á¦Ç° ¼·Ð
½ÃÀå : À¯Çüº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð ¼ºÀå·ü : À¯Çüº°(2020³â/2024³â/2031³â)
±¸Á¦¿ª OÇü
±¸Á¦¿ª OÇü+AÇü
±âŸ
½ÃÀå : ¿ëµµº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð ¼ºÀå·ü : ¿ëµµº°(2020³â/2024³â/2031³â)
Á¤ºÎ Á¶´Þ
Á÷Á¢ ÆÇ¸Å
ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ
Á¶»ç ¸ñÀû
´ë»ó ¿¬µµ
Á¦2Àå ÁÖ¿ä ¿ä¾à
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ Ãß»ê°ú ¿¹Ãø(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Áö¿ªº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Áö¿ªº°(2020³â/2024³â/2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Áö¿ªº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Áö¿ªº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÃÀå Á¡À¯À² : Áö¿ªº°(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å Ãß»ê°ú ¿¹Ãø(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Áö¿ªº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Áö¿ªº°(2020³â/2024³â/2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Áö¿ªº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Áö¿ªº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÃÀå Á¡À¯À² : Áö¿ªº°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù
À¯·´
Áß±¹
¾Æ½Ã¾Æ(Áß±¹ Á¦¿Ü)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä«
Á¦3Àå °¢ Á¦Á¶¾÷üÀÇ °æÀï
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Á¦Á¶¾÷üº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Á¦Á¶¾÷üº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÃÀå Á¡À¯À² : Á¦Á¶¾÷üº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Á¦Á¶¾÷üº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Á¦Á¶¾÷üº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÃÀå Á¡À¯À² : Á¦Á¶¾÷üº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä ±â¾÷, ¾÷°è ¼øÀ§(2024³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å °¡°Ý : Á¦Á¶¾÷üº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü, Á¦Á¶°ÅÁ¡ ºÐÆ÷¿Í º»»ç
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü, Á¦Ç°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü, ¼³¸³ÀÏ
ÀμöÇÕº´(M&A), È®Àå °èȹ
Á¦4Àå ½ÃÀå ±Ô¸ð : À¯Çüº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÇÀû : À¯Çüº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ¿¹Ãø : À¯Çüº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÃÀå Á¡À¯À² : À¯Çüº°(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÇÀû : À¯Çüº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ¿¹Ãø : À¯Çüº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÃÀå Á¡À¯À² : À¯Çüº°(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý : À¯Çüº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý : À¯Çüº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý ¿¹Ãø : À¯Çüº°(2026³â-2031³â)
Á¦5Àå ½ÃÀå ±Ô¸ð : ¿ëµµº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÇÀû : ¿ëµµº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ¿¹Ãø : ¿ëµµº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ½ÃÀå Á¡À¯À² : ¿ëµµº°(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÇÀû : ¿ëµµº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ¿¹Ãø : ¿ëµµº°(2026³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ ½ÃÀå Á¡À¯À² : ¿ëµµº°(2020³â-2031³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý : ¿ëµµº°
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý : ¿ëµµº°(2020³â-2025³â)
¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å °¡°Ý ¿¹Ãø : ¿ëµµº°(2026³â-2031³â)
Á¦6Àå ¹Ì±¹/ij³ª´Ù.
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : À¯Çüº°
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ¿ëµµº°
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ±¹°¡º°
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ±¹°¡º°(2020³â-2031³â)
¹Ì±¹/ij³ª´Ù ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ±¹°¡º°(2020³â-2031³â)
¹Ì±¹
ij³ª´Ù
¸ß½ÃÄÚ
Á¦7Àå À¯·´
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : À¯Çüº°
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°(2020³â-2031³â)
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°(2020³â-2031³â)
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ¿ëµµº°
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°(2020³â-2031³â)
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°(2020³â-2031³â)
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ±¹°¡º°
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ±¹°¡º°(2020³â-2031³â)
À¯·´ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ±¹°¡º°(2020³â-2031³â)
µ¶ÀÏ
ÇÁ¶û½º
¿µ±¹
ÀÌÅ»¸®¾Æ
·¯½Ã¾Æ
Á¦8Àå Áß±¹
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : À¯Çüº°
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°(2020³â-2031³â)
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°(2020³â-2031³â)
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ¿ëµµº°
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°(2020³â-2031³â)
Áß±¹ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°(2020³â-2031³â)
Á¦9Àå ¾Æ½Ã¾Æ(Áß±¹ Á¦¿Ü)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : À¯Çüº°
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°(2020³â-2031³â)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°(2020³â-2031³â)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ¿ëµµº°
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°(2020³â-2031³â)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°(2020³â-2031³â)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : Áö¿ªº°
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : Áö¿ªº°(2020³â-2031³â)
¾Æ½Ã¾Æ ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : Áö¿ªº°(2020³â-2031³â)
ÀϺ»
Çѱ¹
Áß±¹ ´ë¸¸
µ¿³²¾Æ½Ã¾Æ
Àεµ
Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : À¯Çüº°
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : À¯Çüº°(2020³â-2031³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : À¯Çüº°(2020³â-2031³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ¿ëµµº°
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ¿ëµµº°(2020³â-2031³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ¿ëµµº°(2020³â-2031³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ±Ô¸ð : ±¹°¡º°
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ¸ÅÃâ : ±¹°¡º°(2020³â-2031³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«/¶óƾ¾Æ¸Þ¸®Ä« ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å : ±¹°¡º°(2020³â-2031³â)
¶óƾ¾Æ¸Þ¸®Ä«
秵¾ÆÇÁ¸®Ä«
Á¦11Àå ±â¾÷ °³¿ä
United Biomedical
CAHIC
Xinjiang Tecon
ISA Pharmaceuticals
Lytix Biopharma
Merck
OncoTherapy Science
Circio
Stemline Therapeutics
Treos Bio
Á¦12Àå »ê¾÷ üÀΰú ÆÇ¸Å ä³Î ºÐ¼®
ÇÕ¼º ÆéƼµå ¹é½Å »ê¾÷ üÀÎ ºÐ¼®
ÇÕ¼º ÆéƼµå ¹é½ÅÀÇ ÁÖ¿ä ¿øÀç·á
ÁÖ¿ä ¿øÀç·á
¿øÀç·á ÁÖ¿ä °ø±Þ¾÷ü
ÇÕ¼º ÆéƼµå ¹é½Å »ý»ê ¹æ½Ä°ú °øÁ¤
ÇÕ¼º ÆéƼµå ¹é½Å ÆÇ¸Å ¹× ¸¶ÄÉÆÃ
Á¦13Àå ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ¿ªÇÐ
ÇÕ¼º ÆéƼµå ¹é½Å »ê¾÷ µ¿Çâ
ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
ÇÕ¼º ÆéƼµå ¹é½Å ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
Á¦14Àå ¼¼°èÀÇ ÇÕ¼º ÆéƼµå ¹é½Å ÁÖ¿ä Á¶»ç °á°ú
Á¦15Àå ºÎ·Ï
LSH
The global Synthetic Peptide Vaccine market is projected to grow from US$ 114.52 million in 2024 to US$ 189.30 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.36% during the forecast period 2025-2031.
Currently, synthetic peptide vaccines for human use are all in the research and development/trial stage, and the only commercially available vaccines are for veterinary use, mainly swine foot-and-mouth disease vaccines.
The China market for Synthetic Peptide Vaccine is estimated to increase from $ 98.24 million in 2024 to reach $ 161.82 million by 2031, at a CAGR of 7.29% during the forecast period of 2025 through 2031.
The global key manufacturers of Synthetic Peptide Vaccine include United Biomedical, CAHIC, Xinjiang Tecon, ISA Pharmaceuticals, Lytix Biopharma, Merck, OncoTherapy Science, Circio, Stemline Therapeutics, and Treos Bio, etc.
Report Includes
This report presents an overview of global market for Synthetic Peptide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2025, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Synthetic Peptide Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Synthetic Peptide Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Synthetic Peptide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Synthetic Peptide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Synthetic Peptide Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ISA Pharmaceuticals, Lytix Biopharma, CAHIC, United Biomedical, Merck, OncoTherapy Science, Circio, Stemline Therapeutics, and Treos Bio, etc.
Market Segmentation
By Company
United Biomedical
CAHIC
Xinjiang Tecon
ISA Pharmaceuticals
Lytix Biopharma
Merck
OncoTherapy Science
Circio
Stemline Therapeutics
Treos Bio
Segment by Type
FMD Type O
FMD Type O+A
Others
Segment by Application
Government Procurement
Direct Sales
Segment by Region
US & Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Australia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Synthetic Peptide Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Synthetic Peptide Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Synthetic Peptide Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Table of Contents
1 STUDY COVERAGE
1.1 Synthetic Peptide Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Synthetic Peptide Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031
1.2.2 FMD Type O
1.2.3 FMD Type O+A
1.2.4 Others
1.3 Market by Application
1.3.1 Global Synthetic Peptide Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031
1.3.2 Government Procurement
1.3.3 Direct Sales
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Synthetic Peptide Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Synthetic Peptide Vaccine Revenue by Region
2.2.1 Global Synthetic Peptide Vaccine Revenue by Region: 2020 VS 2024 VS 2031
2.2.2 Global Synthetic Peptide Vaccine Revenue by Region (2020-2025)
2.2.3 Global Synthetic Peptide Vaccine Revenue by Region (2026-2031)
2.2.4 Global Synthetic Peptide Vaccine Revenue Market Share by Region (2020-2031)
2.3 Global Synthetic Peptide Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Synthetic Peptide Vaccine Sales by Region
2.4.1 Global Synthetic Peptide Vaccine Sales by Region: 2020 VS 2024 VS 2031
2.4.2 Global Synthetic Peptide Vaccine Sales by Region (2020-2025)
2.4.3 Global Synthetic Peptide Vaccine Sales by Region (2026-2031)
2.4.4 Global Synthetic Peptide Vaccine Sales Market Share by Region (2020-2031)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 COMPETITION BY MANUFACTURERS
3.1 Global Synthetic Peptide Vaccine Sales by Manufacturers
3.1.1 Global Synthetic Peptide Vaccine Sales by Manufacturers (2020-2025)
3.1.2 Global Synthetic Peptide Vaccine Sales Market Share by Manufacturers (2020-2025)
3.2 Global Synthetic Peptide Vaccine Revenue by Manufacturers
3.2.1 Global Synthetic Peptide Vaccine Revenue by Manufacturers (2020-2025)
3.2.2 Global Synthetic Peptide Vaccine Revenue Market Share by Manufacturers (2020-2025)
3.3 Global Key Players of Synthetic Peptide Vaccine, Industry Ranking in 2024
3.4 Global Synthetic Peptide Vaccine Sales Price by Manufacturers (2020-2025)
3.5 Global Key Manufacturers of Synthetic Peptide Vaccine, Manufacturing Base Distribution and Headquarters
3.6 Global Key Manufacturers of Synthetic Peptide Vaccine, Product Offered
3.7 Global Key Manufacturers of Synthetic Peptide Vaccine, Founded Date
3.8 Mergers & Acquisitions, Expansion Plans
4 MARKET SIZE BY TYPE
4.1 Global Synthetic Peptide Vaccine Sales by Type
4.1.1 Global Synthetic Peptide Vaccine Historical Sales by Type (2020-2025)
4.1.2 Global Synthetic Peptide Vaccine Forecasted Sales by Type (2026-2031)
4.1.3 Global Synthetic Peptide Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Synthetic Peptide Vaccine Revenue by Type
4.2.1 Global Synthetic Peptide Vaccine Historical Revenue by Type (2020-2025)
4.2.2 Global Synthetic Peptide Vaccine Forecasted Revenue by Type (2026-2031)
4.2.3 Global Synthetic Peptide Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Synthetic Peptide Vaccine Price by Type
4.3.1 Global Synthetic Peptide Vaccine Price by Type (2020-2025)
4.3.2 Global Synthetic Peptide Vaccine Price Forecast by Type (2026-2031)
5 MARKET SIZE BY APPLICATION
5.1 Global Synthetic Peptide Vaccine Sales by Application
5.1.1 Global Synthetic Peptide Vaccine Historical Sales by Application (2020-2025)
5.1.2 Global Synthetic Peptide Vaccine Forecasted Sales by Application (2026-2031)
5.1.3 Global Synthetic Peptide Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Synthetic Peptide Vaccine Revenue by Application
5.2.1 Global Synthetic Peptide Vaccine Historical Revenue by Application (2020-2025)
5.2.2 Global Synthetic Peptide Vaccine Forecasted Revenue by Application (2026-2031)
5.2.3 Global Synthetic Peptide Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Synthetic Peptide Vaccine Price by Application
5.3.1 Global Synthetic Peptide Vaccine Price by Application (2020-2025)
5.3.2 Global Synthetic Peptide Vaccine Price Forecast by Application (2026-2031)
6 US & CANADA
6.1 US & Canada Synthetic Peptide Vaccine Market Size by Type
6.1.1 US & Canada Synthetic Peptide Vaccine Sales by Type (2020-2031)
6.1.2 US & Canada Synthetic Peptide Vaccine Revenue by Type (2020-2031)
6.2 US & Canada Synthetic Peptide Vaccine Market Size by Application
6.2.1 US & Canada Synthetic Peptide Vaccine Sales by Application (2020-2031)
6.2.2 US & Canada Synthetic Peptide Vaccine Revenue by Application (2020-2031)
6.3 US & Canada Synthetic Peptide Vaccine Market Size by Country
6.3.1 US & Canada Synthetic Peptide Vaccine Revenue by Country (2020-2031)
6.3.2 US & Canada Synthetic Peptide Vaccine Sales by Country (2020-2031)
6.3.3 US
6.3.4 Canada
6.3.5 Mexico
7 EUROPE
7.1 Europe Synthetic Peptide Vaccine Market Size by Type
7.1.1 Europe Synthetic Peptide Vaccine Sales by Type (2020-2031)
7.1.2 Europe Synthetic Peptide Vaccine Revenue by Type (2020-2031)
7.2 Europe Synthetic Peptide Vaccine Market Size by Application
7.2.1 Europe Synthetic Peptide Vaccine Sales by Application (2020-2031)
7.2.2 Europe Synthetic Peptide Vaccine Revenue by Application (2020-2031)
7.3 Europe Synthetic Peptide Vaccine Market Size by Country
7.3.1 Europe Synthetic Peptide Vaccine Revenue by Country (2020-2031)
7.3.2 Europe Synthetic Peptide Vaccine Sales by Country (2020-2031)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 CHINA
8.1 China Synthetic Peptide Vaccine Market Size by Type
8.1.1 China Synthetic Peptide Vaccine Sales by Type (2020-2031)
8.1.2 China Synthetic Peptide Vaccine Revenue by Type (2020-2031)
8.2 China Synthetic Peptide Vaccine Market Size by Application
8.2.1 China Synthetic Peptide Vaccine Sales by Application (2020-2031)
8.2.2 China Synthetic Peptide Vaccine Revenue by Application (2020-2031)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Synthetic Peptide Vaccine Market Size by Type
9.1.1 Asia Synthetic Peptide Vaccine Sales by Type (2020-2031)
9.1.2 Asia Synthetic Peptide Vaccine Revenue by Type (2020-2031)
9.2 Asia Synthetic Peptide Vaccine Market Size by Application
9.2.1 Asia Synthetic Peptide Vaccine Sales by Application (2020-2031)
9.2.2 Asia Synthetic Peptide Vaccine Revenue by Application (2020-2031)
9.3 Asia Synthetic Peptide Vaccine Market Size by Region
9.3.1 Asia Synthetic Peptide Vaccine Revenue by Region (2020-2031)
9.3.2 Asia Synthetic Peptide Vaccine Sales by Region (2020-2031)
9.3.3 Japan
9.3.4 South Korea
9.3.5 China Taiwan
9.3.6 Southeast Asia
9.3.7 India
10 MIDDLE EAST, AFRICA AND LATIN AMERICA
10.1 Middle East, Africa and Latin America Synthetic Peptide Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Synthetic Peptide Vaccine Sales by Type (2020-2031)
10.1.2 Middle East, Africa and Latin America Synthetic Peptide Vaccine Revenue by Type (2020-2031)
10.2 Middle East, Africa and Latin America Synthetic Peptide Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Synthetic Peptide Vaccine Sales by Application (2020-2031)
10.2.2 Middle East, Africa and Latin America Synthetic Peptide Vaccine Revenue by Application (2020-2031)
10.3 Middle East, Africa and Latin America Synthetic Peptide Vaccine Market Size by Country
10.3.1 Middle East, Africa and Latin America Synthetic Peptide Vaccine Revenue by Country (2020-2031)
10.3.2 Middle East, Africa and Latin America Synthetic Peptide Vaccine Sales by Country (2020-2031)
10.3.3 Latin America
10.3.4 Middle East
10.3.5 Africa
11 CORPORATE PROFILE
11.1 United Biomedical
11.1.1 United Biomedical Company Information
11.1.2 United Biomedical Overview
11.1.3 United Biomedical Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.4 United Biomedical Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 United Biomedical Recent Developments
11.2 CAHIC
11.2.1 CAHIC Company Information
11.2.2 CAHIC Overview
11.2.3 CAHIC Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.4 CAHIC Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3 Xinjiang Tecon
11.3.1 Xinjiang Tecon Company Information
11.3.2 Xinjiang Tecon Overview
11.3.3 Xinjiang Tecon Synthetic Peptide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.4 Xinjiang Tecon Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4 ISA Pharmaceuticals
11.4.1 ISA Pharmaceuticals Company Information
11.4.2 ISA Pharmaceuticals Overview
11.4.3 ISA Pharmaceuticals Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5 Lytix Biopharma
11.5.1 Lytix Biopharma Company Information
11.5.2 Lytix Biopharma Overview
11.5.3 Lytix Biopharma Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Overview
11.6.3 Merck Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7 OncoTherapy Science
11.7.1 OncoTherapy Science Company Information
11.7.2 OncoTherapy Science Overview
11.7.3 OncoTherapy Science Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8 Circio
11.8.1 Circio Company Information
11.8.2 Circio Overview
11.8.3 Circio Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.4 Circio Recent Developments
11.9 Stemline Therapeutics
11.9.1 Stemline Therapeutics Company Information
11.9.2 Stemline Therapeutics Overview
11.9.3 Stemline Therapeutics Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10 Treos Bio
11.10.1 Treos Bio Company Information
11.10.2 Treos Bio Overview
11.10.3 Treos Bio Synthetic Peptide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
12.1 Synthetic Peptide Vaccine Industry Chain Analysis
12.2 Synthetic Peptide Vaccine Key Raw Material
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Synthetic Peptide Vaccine Production Mode & Process
12.4 Synthetic Peptide Vaccine Sales and Marketing
13 SYNTHETIC PEPTIDE VACCINE MARKET DYNAMICS
13.1.1 Synthetic Peptide Vaccine Industry Trends
13.1.2 Synthetic Peptide Vaccine Market Drivers
13.1.3 Synthetic Peptide Vaccine Market Challenges
13.1.4 Synthetic Peptide Vaccine Market Restraints
14 KEY FINDINGS IN THE GLOBAL SYNTHETIC PEPTIDE VACCINE STUDY
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer 127